Business Segments · Total other segment expense, net
Oncology & Multispecialty — Total other segment expense, net
McKesson Oncology & Multispecialty — Total other segment expense, net increased by 8.5% to $12.71B in Q4 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ4 2025
How to read this metric
An increase in net expenses suggests rising overhead or non-core costs, while a decrease indicates improved cost management or higher non-operating income.
Detailed definition
Represents the net of miscellaneous operating expenses and income items not directly attributable to core segment operat...
Peer comparison
Similar to 'Other Operating Expenses' or 'Unallocated Segment Costs' found in the segment reporting of other large pharmaceutical distributors.
Metric ID:
mck_segment_oncology_multispecialty_total_other_segment_expense_netHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $8.96B | $9.29B | $11.71B | $12.71B |
| QoQ Change | — | +3.7% | +26.1% | +8.5% |
| YoY Change | — | — | +30.8% | +36.8% |
Range$8.96B – $12.71B
Avg YoY Growth+33.8%
Median YoY Growth+33.8%
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — total other segment expense, net?
- McKesson (MCK) reported oncology & multispecialty — total other segment expense, net of $12.71B in Q4 2025.
- What does oncology & multispecialty — total other segment expense, net mean?
- The net total of miscellaneous operating expenses and income items for the Oncology and Multispecialty segment.